Shushan Hovsepyan: Does the choice of chemotherapy regimen make a difference in relapse/progressive high-risk neuroblastoma?

Shushan Hovsepyan, Pediatric Oncologist and Clinical Research Coordinator at the Yeolyan Hematology and Oncology Center, shared the following post on LinkedIn:

“Does the choice of chemotherapy regimen make a difference in relapse/progressive high-risk neuroblastoma?

Here’s what we learned from France’s real-world data on chemo-immunotherapy:

– Thirty-nine patients with relapsed/progressive high-risk neuroblastoma receiving chemo-immuno.
– Similar overall response rates (42% with dinutuximab beta + TopoCyclo and 40% with dinutuximab beta + TOTEM/TEMIRI) were observed.
– Generally safe profile, with mild to moderate adverse effects.
– The median follow-up time for progression-free survival (PFS) and overall survival (OS) was 10 months, 9-month PFS and OS rates were 32% and 53%, respectively.

These findings underscore the significance of chemo-immunotherapy in treating neuroblastoma, irrespective of the specific chemotherapy regimen.”

Read further.
Source: Shushan Hovsepyan/LinkedIn